Podcasts about Chronic kidney disease

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - (Iris Art in first question!) 00:01:37 - Stage 4 Breast Cancer - ER/PR-Positive HER2-Negative 00:48:30 - Chronic Kidney Disease (CKD) Stage 5 - On hemodialysis 3x/week after Fluid Retention 00:59:48 - Benign Parotid Tumor (Left) - Trigeminal Neuralgia - Food Cravings - Diet Question 01:06:27 - Should I eliminate Bioidentical Hormones? 01:21:33 - Depersonalization/Derealization - Social anxiety - Shyness Low self-esteem - Update 00:01:37 - Stage 4 Breast Cancer - ER/PR-Positive HER2-Negative I have not done anything conventional, my breast is hard, like a rock. 00:48:30 - Chronic Kidney Disease (CKD) Stage 5 - On hemodialysis 3x/week after Fluid Retention Is it possible for both kidneys affected by stage 5 kidney failure to recover without a transplant?  00:59:48 - Benign Parotid Tumor (Left) - Trigeminal Neuralgia - Food Cravings - Diet Question Eye Analysis  01:06:27 - Should I eliminate Bioidentical Hormones? I have Postherpetic Neuralgia (PHN) after having the shingles for 3 long, painful months. 01:21:33 - Depersonalization/Derealization - Social anxiety - Shyness Low self-esteem - Update Eye Picture Analysis - Spirituality

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. Lots going on in this new episode! Three new pieces of research and an interview with Dr Anna Martinez, consultant paediatric dermatologist at GOSH, talking about a skin fragility condition many of us may not have heard of before - epidermolysis bullosa - in conjunction with DEBRA, the leading charity for EB awareness and research. In research, we look at two papers published this week in finerenone. Does it have a role in CKD management in patients without diabetes, and if so, how good is it?Second, retatruide - the latest injectable weight loss medication making a splash across the headlines - could it be used as monotherapy for recent onset type 2 diabetes?ResourcesNB Medical Epidermolysis bullosa free online educational moduleDEBRANEJM Finerenone for CKDLancet Finerenone MALancet Retatrutide for early T2DMwww.nbmedical.com/podcast

https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Definition and KDIGO Staging (1:47),Screening for CKD (4:30).Diabetic Nephropathy (6:22),Hypertensive Nephrosclerosis (8:17),Nephrotoxic Medications (9:53),Autosomal Dominant Polycystic Kidney Disease (12:07),IgA Nephropathy (14:06),Minimal Change Disease (15:06),FSGS (15:55),Membranous Nephropathy (16:26),Anemia of CKD (16:52),Mineral Bone Disorder (18:40),Hyperkalemia (21:11),Metabolic Acidosis (23:40),Volume Overload (25:25),Uremia (25:50),Renal Replacement Therapy (28:35),Practice Questions (31:43)

Tumi Mudumela shares with us how she is implementing her findings from her MBA research, Early screening for Chronic Kidney DIsease and interventions pre-dialysis can change the disease trajectory for a patient.Join us on the 28 May 2026 at 12pm CAT on www.vukaonlineradio.co.za as we have a chat with our host Colleen and special guest Tumi Mudumela.Be sure to join us! #Vuka #Healthcare #Medical

In this episode of the MyHeart.net podcast, Dr. Alain Bouchard is joined by Dr. Norman Winn Seay to discuss chronic kidney disease, the connection between obesity and kidney health, and how early awareness, lifestyle changes, and newer medications can help protect kidney function.To learn more about kidney health and chronic kidney disease, explore our lastest article, Why Obesity Matters for Kidney Health.About the TeamDr. Alain Bouchard is a clinical cardiologist at Cardiology Specialists of Birmingham, AL. He is a native of Quebec, Canada and trained in Internal Medicine at McGill University in Montreal. He continued as a Research Fellow at the Montreal Heart Institute. He did a clinical cardiology fellowship at the University of California in San Francisco. He joined the faculty at the University of Alabama Birmingham from 1986 to 1990. He worked at CardiologyPC and Baptist Medical Center at Princeton from 1990-2019. He is now part of the Cardiology Specialists of Birmingham at UAB Medicine.Dr. Philip Johnson is originally from Selma, AL. Philip began his studies at Vanderbilt University in Nashville, TN, where he double majored in Biomedical and Electrical Engineering. After a year in the “real world” working for his father as a machine design engineer, he went to graduate school at UAB in Birmingham, AL, where he completed a Masters and PhD in Biomedical Engineering before becoming a research assistant professor in Biomedical Engineering. After a short stint in academics, he continued his education at UAB in Medical School, Internal Medicine Residency, and is currently a cardiology fellow in training with a special interest in cardiac electrophysiology.Medical DisclaimerThe contents of the MyHeart.net podcast, including as textual content, graphical content, images, and any other content contained in the Podcast (“Content”) are purely for informational purposes. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or heard on the Podcast!If you think you may have a medical emergency, call your doctor or 911 immediately. MyHeart.net does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Podcast. Reliance on any information provided by MyHeart.net, MyHeart.net employees, others appearing on the Podcast at the invitation of MyHeart.net, or other visitors to the Podcast is solely at your own risk.The Podcast and the Content are provided on an “as is” basis.

In Part 2, Pranav Garimella discusses major advances in diabetic kidney disease management. Learn how sodium-glucose cotransporter 2 (SGLT2) inhibitors and novel therapies are reshaping disease progression, and why early intervention is critical to improving long-term outcomes. Timestamps: 01:07 – Practice-changing developments 05:10 – GLP-1 agonists 07:00 – Early intervention 08:43 – Unmet needs

In the final episode, Pranav Garimella explores glomerular and cystic kidney diseases, including IgA nephropathy and autosomal dominant polycystic kidney disease. Discover how personalised medicine, biomarkers, and earlier diagnosis are shaping the future of care in these complex conditions. Timestamps: 01:11 – Current treatment for IgA nephropathy 02:24 – SGLT2 inhibitors 03:38 – Cystic kidney disease diagnosis

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health -Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: -Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 -Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 -Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 -Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

In this rapid-fire episode, Pranav Garimella answers key questions on chronic kidney disease, from early detection and screening challenges to future innovations in nephrology. A concise overview for clinicians and curious listeners alike.

Pranav Garimella joins host Catherine Glass to explore why early detection of chronic kidney disease remains challenging. From high-risk populations to emerging plasma and urine biomarkers, this episode examines how earlier diagnosis and improved risk stratification can transform patient outcomes. Timestamps: 00:59 – Challenges of early detection 05:12 – Populations for intensive screening 09:08 – Plasma and urine biomarkers 13:45 – Biomarker-driven risk stratification

Guest: Deborah Clegg, PhD For decades, potassium restriction has been a cornerstone of dietary management in patients with chronic kidney disease (CKD), but is it always necessary? Here to answer that exact question is Dr. Deborah Clegg. Since many patients may already be consuming potassium at restricted levels, she emphasizes the importance of individualized dietary assessment before imposing further limitations. Dr. Clegg is the Vice President for Research and a Professor in the Department of Internal Medicine at Texas Tech University Health Sciences Center in El Paso.

This ISN i3C podcast brings together leading ISN experts to unpack a new paper tackling one of nephrology's biggest mysteries: chronic kidney disease of unknown origin (CKDu). The discussion explores why identifying the causes of CKDu has been so challenging—highlighting gaps in terminology, study design, and data collection—while questioning whether current research approaches are asking the right questions. Through expert insights and debate, the podcast emphasizes the need for standardized methods, stronger global collaboration, and a shift toward translating research into prevention, especially in low- and middle-income countries. The podcast closes by looking ahead to priority research areas and how the global community can get involved in advancing solutions. Listeners will come away with a deeper, more nuanced understanding of CKDu.Participants: Ben Caplin (UK), ISN i3C Working Group ChairMagdalena Madero (Mexico), ISN i3C Working Group Deputy ChairEranga Wijewickrama (Sri Lanka)Shuchi Anand (United States) 

In this insightful episode of the Homeopathy247 podcast, host Mary sits down with homeopath Madhavi Naik to discuss a modern epidemic: adrenal fatigue and burnout. They explore why so many high-functioning individuals find themselves completely depleted and how homeopathy offers a unique, individualized path to restoring the body's natural energy and balance. Understanding Adrenal Fatigue and Burnout Adrenal fatigue isn't an official medical diagnosis, but rather a collection of symptoms resulting from prolonged stress without adequate recovery. Madhavi explains that burnout is not just physical tiredness; it is a vital force depletion that affects a person mentally, emotionally, and intellectually. In our modern, overstimulated world, long work hours, excessive screen time, and a lack of downtime prevent our nervous systems from resetting. High-functioning, ambitious individuals, students, and active caregivers are particularly prone to pushing themselves until their bodies simply cannot keep up. The Medical vs. Homeopathic Approach When a patient visits a conventional doctor for chronic exhaustion, standard blood tests (like liver function or cortisol levels) often return "normal" or inconclusive results. Because there is no official diagnosis, patients are frequently dismissed and simply told to rest or take supplements. A homeopath, however, looks at the whole person. They dive deep into the emotional causes (stress, grief, mental overload) and observe the patient's unique energy patterns—whether they are "wired" and pushing through or have completely collapsed. Individualized Care: Two Contrasting Cases Madhavi shares two powerful cases that illustrate why homeopathy requires personalized prescribing: The Nux Vomica Case: A male tech worker in his 40s came in with severe bloating, acidity, and constipation. He was juggling multiple time zones, sacrificing sleep, and relying heavily on caffeine, nicotine, and alcohol to cope. He became highly irritable and impatient with his coworkers. After a single dose of Nux Vomica 30c, his emotional irritability calmed first, followed by improved sleep and the slow return of his physical energy. The Phosphoric Acid Case: A woman in her 30s, also in tech, experienced profound exhaustion and apathy after her hard work on a year-long project was ignored. Her disappointment led to total indifference—she stopped engaging at work to the point of risking her job. Unlike the irritable Nux Vomica patient, she was completely drained. After receiving Phosphoric Acid 200c, she began emotionally engaging with her life and work again. The Role of Lifestyle and Supplements Madhavi notes that while homeopathic remedies balance the vital force, lifestyle changes are essential. Setting boundaries, reducing screen time, practicing gentle movement (like yoga or walking), and ensuring proper nutrition are vital steps to prevent and recover from burnout. She also clarifies that while caffeine borrows energy from the body, and supplements only address nutritional deficiencies, homeopathy provides the necessary "reset" for a dysregulated nervous system. Important links mentioned in this episode Madhavi Naik's website: https://naturalbridgeshomeopathy.com/ Read more about Madhavi: https://homeopathy247.com/professional-homeopaths-team/madhavi-naik/ Download Joanna's ebooks: Getting Started with Homeopathy: https://free.homeopathy247.com/homeopathy-getting-started Homeopathy for Chronic Kidney Disease: https://free.homeopathy247.com/chronic-kidney-disease Homeopathy for Thyroid Balance: https://free.homeopathy247.com/thyroid-balance   Subscribe to our YouTube channel and be updated with our latest episodes. You can also subscribe to our podcast channels available on your favourite podcast listening app below: Apple Podcast: https://podcasts.apple.com/us/podcast/homeopathy247-podcast/id1628767810 Spotify: https://open.spotify.com/show/39rjXAReQ33hGceW1E50dk Follow us on our social media accounts: Facebook: https://www.facebook.com/homeopathy247 Instagram: https://www.instagram.com/homeopathy247 You can also visit our website at https://homeopathy247.com/

In this episode of the RCP Medicine Podcast, Professor Jeremy Levy, consultant nephrologist in London, joins Dr Alex Crowe, consultant physician in Liverpool, for an insightful and practical conversation about chronic kidney disease (CKD). Together, they explore why CKD is so common, and often silent. How to distinguish acute from chronic kidney problems, and which investigations matter most.The discussion also highlights the growing importance of cardiorenal metabolic medicine, offering clinicians a clear approach to assessing risk, optimising treatment, and supporting long‑term health. From EGFR trends to SGLT2 inhibitors, from lifestyle change to coding accuracy, this episode provides an essential, up‑to‑date guide for managing CKD in everyday practice.Resources For kidney sake podcast:  Home | ForKidneysSake.com Excellent resources on CKD here from NHS NW London:  Chronic kidney diseaseNICE guidelines: Overview | Chronic kidney disease: assessment and management | Guidance | NICE Hypertension in CKD from UK kidney association  FINAL UKKA NICE-KDIGO commentary December 2022.pdfExercise and Lifestyle in CKD from UK kidney association   Exercise and Lifestyle in CKD clinical practice guideline33_v4_FINAL_0.pdf SGLT2i in CKD  from UK kidney association  Sodium Glucose Co transporter 2 - UK Kidney Association.KDIGO (international) guidelines on CKD management   CKD Evaluation and Management – KDIGOKIDGO prognosis of CKD by Albuminuria Categories: KIDGO 2012 S126American Diabetes Association guidelines including CKD   Volume 48 Issue Supplement_1 | Diabetes Care | American Diabetes AssociationFor Kidneys SakeFor Kidneys Sake is a clinician-led podcast from Imperial College Healthcare NHS Trust and North West London Integrated Care Board, offering practical, evidence-based insight into chronic kidney disease and cardio-renal care. Through short, accessible conversations with experts across primary and secondary care, the series supports shared learning on CKD detection, risk management and integrated patient care. The podcast is for GPs, pharmacists, nurses and multidisciplinary teams, and is relevant for clinicians, patients and anyone interested in improving kidney health.Explore our CPD portfolio by your career stageRCP | Education and professional developmentRCP LinksEducationRCP Social MediaInstagramLinkedInFacebookBlueskyMusic Episode 50 onward - Bensound.com  Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

In this episode, the third in the series detailing my journey with chronic kidney disease, Jeremy Opperman and I continue the story from where we left off.Today we discuss how I went about finding a possible kidney donor, and the various types of donors there are. We then explore the range of medical tests my possible donor and I underwent to ensure we were a viable match, and all that is happening in the meantime Now that I am awaiting a date for the surgery, I describe my emotions as I approach the final stages of this journey. Listen to the first two episodes in the series:138 My Journey with Chronic Kidney Disease: From Diabetes to dialysis, about being diagnosed with type 1 diabetes as a child, navigating diabetes and my subsequent blindness, and finishing with the diagnosis of chronic kidney disease.Link: https://rss.com/podcasts/different-way-of-seeing/2597760139 – My Journey with Chronic Kidney Disease: From Dialysis to Hope, about understanding what dialysis is, how I've adapted to the medical regime, and ending up discussing the possibility of a kidney transplant operation.Link: https://rss.com/podcasts/different-way-of-seeing/2597759 Image Description:A woman with shoulder-length dark brown hair who is lying on a reclinable medical bed. Beside her is a dialysis machine with various displays. The backrest of the bed is in an upright position. I'd love to hear from you – contact me atWebsite : loisstrachan.comLinkedIn: www.linkedin.com/in/lstrachanFacebook: https://www.facebook.com/loisstrachanspeaker This episode edited by Craig Strachan using Hindenburg PRO – find out more on Hindenburg.comCredits and music by Charlie Dyasi.

This issue will review: 1.     Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide 2.     Estimated Optimal Individualized Diabetes Risk Prediction From Preventive Interventions in the U.S. General Population 3.     Impact of Metabolic Bariatric Surgery on Weight Loss and Glycemic Control in Adults With Type 1 Diabetes 4.     Finerenone in Type 1 Diabetes and Chronic Kidney Disease 5.     Effects of Sodium/Glucose Cotransporter-2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's science and medical journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE, and beyond. Each episode is approximately 25 minutes long and presents recently published articles from ADA journals and more. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this episode, host Dr. Srinath Yadlapalli and guest Dr. Kristina Bryant discuss measles' diagnosis, prevention, management, and how dialysis centers can prepare for outbreaks.

In this episode, host Dr. Srinath Yadlapalli and guest Dr. Kristina Bryant discuss measles' diagnosis, prevention, management, and how dialysis centers can prepare for outbreaks.

Send us Fan MailPaper Discussed in this Episode:Assessing interstitial fibrosis and tubular atrophy in kidney biopsies artificial intelligence versus humans. Farris AB, Zukić D, Solez K. Current Opinion in Nephrology and Hypertension. March 16, 2026.Episode Summary: In this journal club deep dive on the Digital Pathology Podcast, we explore the intense debate over quantifying chronic kidney disease progression. We unpack a fresh 2026 study comparing artificial intelligence to human pathologists in assessing interstitial fibrosis and tubular atrophy. If top experts can't agree on a diagnosis due to human subjectivity, can an AI trained on their imperfect data provide a better standard? We explore what happens when pixel-perfect machines clash with nuanced human medical judgment.In This Episode, We Cover:• The Clinical Stakes of Kidney Scarring: Why interstitial fibrosis (the scarring of tissue spaces between filtering units) and tubular atrophy (shrinking and collapsing functional tubes) are the primary surrogate measures for tracking chronic kidney disease. We discuss how a mere 10% diagnostic variance can drastically alter a patient's medication regimen, dialysis prep, or transplant eligibility.• The Flaw in the "Gold Standard": We break down the "interobserver variability" problem—why two highly trained, board-certified pathologists can look at the exact same biopsy slide and give two completely different mathematical assessments of the damage.• How the AI Actually Works (Mapping the Neighborhood): A look at "indirect assessment through kidney compartment segmentation," where the AI acts as a digital surveyor. It identifies cellular fences like glomeruli and tubules, establishing microscopic "zoning laws" before it begins counting the damaged tissue.• The Proofreader vs. The Literary Critic: Why studies show a persistent "lack of complete concordance" between human and machine. We discuss how AI hyper-focuses on mathematical pixel intensity and mistakes physical slide artifacts (like a folded piece of tissue) for severe disease. Meanwhile, human pathologists act as "literary critics," easily filtering out the visual noise using clinical context.• The Humans + AI Synergy: The ultimate endgame isn't replacing pathologists, but combining the tireless mathematical consistency of AI with the complex contextual reasoning of humans to create a highly advanced co-pilot system.Key Takeaway: The lack of perfect agreement between AI and human pathologists isn't a failure, but rather evidence that they perform fundamentally different types of analysis. AI excels at tedious, reproducible quantification that eliminates human visual fatigue, but it lacks contextual judgment. By adopting a "humans + AI" workflow, the medical field can stabilize crucial kidney measurements and elevate the pathologist to a true diagnostic synthesizer, ultimately leading to more effective patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative landscape of the pharmaceutical and biotechnology sectors, where scientific innovation, regulatory progression, and strategic adjustments define the industry's current trajectory.A significant spotlight is on Bayer's recent clinical success with Kerendia (finerenone) in treating non-diabetic chronic kidney disease (CKD). Previously approved for CKD linked with type 2 diabetes, the positive outcomes from the FIND-CKD study suggest an expanded therapeutic scope for Kerendia. This advancement not only enhances Bayer's foothold in nephrology but provides a potential new treatment avenue for millions suffering from CKD without diabetes, underscoring the urgent global need to address this chronic condition effectively.In parallel, Eli Lilly's promising Phase 3 trial results for Ebglyss, an IL-13 inhibitor intended for atopic dermatitis in children, signal a potential expansion of treatment options for younger patients. Atopic dermatitis can severely impact quality of life, and Lilly's progress illustrates a broader industry commitment to fulfilling unmet medical needs across various patient groups.Turning to regulatory achievements, AstraZeneca's Imfinzi has secured European Union approval for perioperative use in gastric cancer treatment. This development underscores a growing regulatory momentum favoring oncology therapies and highlights an increasing emphasis on perioperative cancer care. Such advancements are crucial as they aim to improve surgical outcomes and enhance long-term survival rates for cancer patients.The industry is also navigating significant challenges as major drug patents approach expiration in 2026. The looming end of exclusivity spells increased competition from generics and presses companies to innovate or optimize mature product portfolios. This situation necessitates strategic agility as firms endeavor to sustain revenue streams amid pricing pressures.In a legal context, Johnson & Johnson has filed a lawsuit against a former oncology employee now associated with Summit Therapeutics, alleging theft of trade secrets. This case highlights the intense competitive nature within biopharma and the critical importance of protecting intellectual property in a fiercely contested market.Meanwhile, Structure Therapeutics has reported compelling phase results for aleniglipron, an oral GLP-1 drug candidate achieving a 16% weight loss efficacy. This positions aleniglipron as a strong player in obesity management innovations, showcasing ongoing advancements in metabolic disease treatment strategies. The drug demonstrated significant weight loss results over 44 weeks in Phase 2 trials, setting the stage for further program launches this year and suggesting potential competition with industry leaders like Novo Nordisk and Eli Lilly by offering less invasive therapy alternatives.BioMarin's reassessment of its clinical strategies for Voxzogo studies reflects mounting competition in treating achondroplasia. This move illustrates broader industry challenges where companies must balance development priorities against competitive pressures effectively. However, BioMarin has faced setbacks after temporarily halting dosing and enrollment in two studies of its growth-related drug Voxzogo due to safety concerns following hip injury reports. This development emphasizes vigilance in monitoring drug safety profiles during trials within competitive therapeutic areas.Amazon's intriguing entry into healthcare with its AI health agent marks a potential revolution in patient engagement by delivering personalized health insights and enhancing access to healthcare professionals. This convergence of technology and healthcare bears significant implications for future patient care delivery models.RegulatSupport the show

In this special edition on Obesity as a Chronic Disease our host, Dr. Neil Skolnik will discuss epidemiology, pathophysiology and screening for CKD in People with Diabetes. This special episode is supported by an independent educational grant from Bayer. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Holly Kramer, M.D., Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University Chicago, past-president of the National Kidney Foundation, Editor-in-Chief of the National Kidney Foundation's journal,  Advances in Kidney Disease and Health (AKDH).   Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 . The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260  

Doctors Lisa and Sara talk to Consultant Nephrologist Dr James Tollitt about Chronic Kidney Disease. We started by defining this and asking detailed questions on diagnosis, pitfalls to avoid, before getting his advice on risk stratifying patients and options for management. Excellent key messages with some easy practice pointers to take away that will benefit your patients and practice.  Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: NICE CKD Chronic kidney disease: assessment and management (last updated Nov 2021, accessed Feb 2026): https://www.nice.org.uk/guidance/ng203/chapter/recommendations GP Notebook Deteriorating eGFR (how to spot accelerating decline in renal function and advice on how to approach this): https://gpnotebook.com/en-GB/pages/renal-medicine/deteriorating-egfr-in-ckd The British Journal of General Practice: The National CKD Audit: a primary care condition that deserves more attention. Aug 2018: https://pmc.ncbi.nlm.nih.gov/articles/PMC6058639/ Ipsos MORI poll from 2014 looking at what the Public know about Kidneys: https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/2015/01/Think-Kidneys-Report-270115-Understanding-what-the-public-know-about-their-kidneys-and-what-they-do.pdf Liu et al. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med Oct 2021. https://pubmed.ncbi.nlm.nih.gov/34459844/ Clinical Digital Resource Collaborative: Renal Disease Search tools (EMIS and SystemOne): https://cdrc.nhs.uk/resources/systmone-resource-centre/specialties/systmone-renal-urology-overview/chronic-kidney-disease-ckd/ The Kidney Failure Risk Equation (UK): https://www.kidneyfailurerisk.co.uk/ ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Dismal prediction that, by 2050, 60% of women will suffer from cardiovascular disease; Yes, it's true that childhood and adolescent obesity, once rare, is now soaring; Treatments for osteopenia; Dentists continue to write prescriptions for potentially deadly antibiotic; A man, in love with his Chatbot, commits suicide to join her in the virtual world; Olive oil is calorie dense—but its consumption results in weight loss; Can “bio-regulator peptides” stave off kidney failure?

 In this episode, Dr. Annoushka Ranaraja  discusses the relationship between Chronic Kidney Disease and osteoporosis based on a case study of a 68 yo female with CKD who sustained a pelvic fracture. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7555655/ Want to make sure you stay up to date in all things Geriatrics in less than 3 minutes every other week? Join thousands of others in our free MMOA Digest Email list - https://institute-of-clinical-excellence.kit.com/a3837f54b7

This episode is a deep dive into chronic kidney disease, applying the guidelines to various case-based scenarios. Zero to GP podcast: https://www.buzzsprout.com/2590332Zero to GP YouTube channel: https://www.youtube.com/@ZeroToGPZero to AKT course: https://zerotofinals.com/courses/zerotoakt/Books: https://zerotofinalsshop.com/

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

Episodio completo aquí: https://youtu.be/3jOy_X4hIwANathaly Marcus, su historia: De un diagnóstico imposible a ayudar a sanar a miles de personasPor primera vez, Nathaly abre su corazón para compartir su historia, marcada por un “no se puede hacer más” y por ser una madre de 25 años que buscó todas las alternativas para sacar adelante a sus hijas prematuras. ❤️‍

Dr. Adam Striker speaks with Dr. Jason Chi, editor for Summaries of Emerging Evidence (SEE), about two topics featured in SEE Volume 42A: the relationship between sedation type and the rate of precancerous polyp detection in colonoscopies, and rates of respiratory and acute cardiovascular complications, as well as 30-day mortality in patients with chronic kidney disease who received neuromuscular blocking agents (NMBAs). Recorded January 2026.

There are moments in life that change everything. In this episode of Everything Is Personal, we sit down with Dr. Matt Harmody a retired ER physician, endurance athlete, and living kidney donor who made one of the most selfless decisions imaginable — giving the gift of life to a stranger. From losing his father to kidney disease, to returning to medical school at 30, to working in emergency medicine and eventually donating his own kidney, this conversation explores resilience, discipline, purpose, and what it truly means to live for something bigger than yourself. We talk about stress, sleep, health, kidney disease, living donation, endurance, emotional strength, and why ordinary people are capable of extraordinary acts. EndoDNA: Where Genetic Science Meets Actionable Patient Care EndoDNA bridges the gap between complex genomics and patient wellness. Our patented DNA analysis platforms and AI technology provide genetic insights that support and enhance your clinical expertise. Click here to check out to take control over your Personal Health & Wellness   Connect with EndoDNA on SOCIAL: IG | X | YOUTUBE | FB Connect with host, Len May, on IG     Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. Darren would like us to make you all aware that he has working relationships with pharmaceutical industry partners. Specifically, that he has received speak fees and consultancy fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Bayer, and Lilly, and has been part of collaborative working agreements with Novartis, Boehringer Ingelheim, and AstraZeneca. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

I know 2026 feels like it ihas been here for months, but only a few weeks ago we were celebrating the nephrology accomplishments of 2025. The New Filtrate came together to review the year.The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn Editor in Chief of Kidney International Case ReportsAnna Gaddy (@AnnaGaddy) Winner of NephJC Rookie of the Year 2020Nayan Arora (@CaptainChloride.bsky.social)AC (@medpeedskidneys.bsky.social)Vipin Verghese (@vipvargh.bsky.social) co-winner of NephJC Engaged Scientist of the Year in 2021Brian Rifkin (@brianrifkin.bsky.social) Co-Editor in Chief NephJC. Winner of NephJC Rookie of the Year 2021Cristina Popa (@NephroSeeker) Co-Editor in Chief NephJC. Wwinner of NephJC Rookie of the Year 2022 and MVP 2023Editing and Show Notes byAnna Gaddy and Joel TopfThe Kidney Connection written and performed by Tim YauShow NotesTop Stories in Nephrology 2025 (NephJC)First Top sories in Nephrology 2010! (Renal Fellow Network)Links to all of the Top Stories in Nephrology, hosted on NephJC since 2017 (NephJC)1. IgA NephropathyVISIONARY: Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial (NEJM)ORIGIN 3: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (NEJM)APPLAUSE-IgA Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (NEJM)Aliza M. Thompson, MD, MS (ASN) 2. Lupus NephritisREGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis (NEJM)3. Nobel prize winner and peripheral immune tolerance4. Xenotransplantation5. GLP1ra RevolutionRemodel REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide (Kidney International)SURPASS-CVOT Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases (Kidney Week abstract in JASN)Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (KFF survey)6. GDMT implementation in CKD: lessons learnt from CONFIDENCE and MIRO-CKDConfidence Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (NEJM)MIRO-CKD Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial (The Lancet)7. Flozin Meta analysisSMART-C. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria. A Meta-Analysis (JAMA)SMART-C. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria. A Meta-Analysis (JAMA)8. Paradigm Shift: Aiming for CKD Remission9. Fish Oil and DialysisPISCES Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM)10. Decline in Dialysis Patients in the United StatesUSRD 2025 Annual Data Report (USRDS)Tubular SecretionSwapnil Hiremath Alien Earth on FX Hulu (Wikipedia)AC A Christmas Carol by Charles Dickens (Wikipedia) and The Muppet Christmas Carol (Wikipedia)Anna Monty Don (Wikipedia)Nayan Back Street Boys at The Sphere (Wikipedia)Brian Marty Supreme (Wikipedia)Cristina The Yellow Tie (Wikipedia)Vipin Stranger Things, good for a four year old? (Wikipedia)Joel Crash Course: The Universe with Katie Mack and John Green (Apple PodCasts)

Amy and Deann talk about The Real Housewives of Beverly Hills. But first Amy serves up some dish on Bethenny Frankel's Stage 2 Chronic Kidney Disease diagnosis and the reactions it sparked. The duo also covers the whirlwind events of Kyle Richards' white party, including filming for Housewives' road trip, and Deanna's unexpected attendance. Additional discussions include Rachel Zoe's shopping adventures, Amanda's heartbreaking loss and psychic reading, and Dorit's biggest misstep yet. They wrap up with their thoughts on Sutton and Jennifer's mini fight and Dorit's upcoming memoir ‘Unburdened.' Plus, get insights on mixing vintage pieces in your lifestyle and some fun anecdotes about Facebook Marketplace.Jones Road BeautyModern Day clean makeup. Jonesroadbeauty.com For a limited time our listeners are getting a free Cool Gloss on their first purchase when they use Code: DRAMAGrow TherapyWhatever challenges you're facing, Grow Therapy is here to help. GrowTherapy.com/DRAMAFor more Drama, Darling, and exclusive content, subscribe to: http://Patreon.com/dramadarling Follow Drama, Darling on Instagram: https://www.instagram.com/dramadarlingshow/   Email Drama, Darling with YOUR comments, questions and drama:  DramaDarlingz@gmail.com Follow Amy Phillips on Instagram: https://www.instagram.com/dramadarlingshow/   MERCH Drama Darling Shop https://drama-darling-shop.printify.me/

Chronic kidney disease (CKD) now affects about 788 million adults worldwide, more than double the number in 1990, making it one of the most widespread and underrecognized health threats A recent systematic analysis published in The Lancet revealed that CKD is now the ninth leading cause of death globally, responsible for roughly 1.48 million deaths in 2023 alone High blood sugar, elevated blood pressure, and excess body weight are the leading drivers of CKD worldwide, together accounting for most of the disease's overall health burden Early-stage CKD affects over 13% of the adult population globally, yet most cases remain undiagnosed because symptoms often don't appear until the disease is advanced You can lower your risk of CKD by keeping your blood pressure and blood sugar in check, getting regular movement, staying hydrated, reducing processed foods, and supporting kidney function with balanced nutrition

Chronic kidney disease affects around one in ten people in Ireland and is on course to becoming the fifth leading cause of death globally by 2040. Despite the opt-out organ donation system, less people donated organs in 2025 compared to the previous year, Adrian Cummins, Head of the Restaurants Association of Ireland was diagnosed with kidney disease in 2019. He spends more than 10 hours a week on dialysis as he waits for a kidney transplant. Adrian joined Pat on the show the show this morning.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

Enhance dialysis-dependent chronic kidney disease (DD-CKD) anemia outcomes through team-centered care and better understanding of new treatment options. Credit available for this activity expires: 12/19/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/elevating-anemia-care-new-strategies-dialysis-dependent-2025a1000zpg?ecd=bdc_podcast_libsyn_mscpedu

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chronic Kidney Disease (CKD) explained, including causes and pathophysiology, as well as symptoms and complications. We also look at diagnosis and treatment options. PDFs available here: https://rhesusmedicine.com/pages/nephrologyConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Chronic Kidney Disease?1:45 Chronic Kidney Disease Symptoms & Complications4:51 Chronic Kidney Disease Causes7:20 Chronic Kidney Disease Pathophysiology 8:14 Chronic Kidney Disease Epidemiology / Risk Factors 8:53 Chronic Kidney Disease Diagnosis10:30 Chronic Kidney Disease Treatment LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesNICE Clinical Knowledge Summaries (CKS). Definition of Chronic Kidney Disease. Last revised May 2025. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/background-information/definition/ (NICE)StatPearls. Chronic Kidney Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Last updated July 31 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK535404/ (NCBI, PubMed)Wikipedia contributors. Chronic kidney disease. Last updated August 2025. Available at: https://en.wikipedia.org/wiki/Chronic_kidney_disease (Wikipedia)GPCPD (HEIW Wales). Prescribing in Acute Kidney Injury (AKI). Updated 2025. Available at: https://gpcpd.heiw.wales/clinical/acute-kidney-injury-in-primary-care/prescribing-in-aki/Kidney International. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 2022 Apr;12(1):7–11. Available at: https://www.kidney-international.org/article/S0085-2538(22)00518-X/fulltext (PubMed)Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

Cyrus Khambatta, Ph.D., Sean Hashmi, M.D., MS, FASN, and Robby Barbaro, MPH, provide evidence-based diet and lifestyle strategies proven to prevent diabetes and chronic kidney disease. Learn actionable steps to transform your health through nutrition. #DiabetesPrevention #KidneyHealth #DietaryStrategies

A special filmed edition of Diary of a Kidney Warrior Podcast is coming on Monday 1st December!   In this listener-led conversation, menopause specialist Dr Vikram returns to answer the questions sent in by the Kidney Warrior community about menopause and chronic kidney disease (CKD).   This new edition continues the important discussion from Episode 142: Breaking the Silence: Menopause and CKD.

Are you actively and appropriately screening for chronic kidney disease (CKD) in your patients with cardio-kidney-metabolic (CKM) conditions? Credit available for this activity expires: 11/26/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/screening-action-addressing-chronic-kidney-disease-reduce-2025a1000wsi?ecd=bdc_podcast_libsyn_mscpedu

With November being disability awareness month in South Africa and 14 November being the annual day dedicated to recognising those living with diabetes, it seemed an appropriate time to publish this interview. In this special two-part episode, I unpack my journey with chronic kidney disease in conversation with Jeremy Opperman. In episode 138, we discuss my diagnosis with Type 1 diabetes when I was six years old and trace the impact of diabetes on my life, resulting in my blindness at the age of 21. We then turn to my subsequent discovery that I was experiencing chronic kidney disease and track the steps that led to my starting on dialysis in January 2025. In episode 139 we explore how I've adapted to dialysis as a blind woman, trying to offer insights into some of the medical realities. Finally, we discuss what the future holds as I start to discover more about a possible kidney transplant. *Note: this conversation was recorded a few months ago and much has changed since then. I now have a kidney donor and am working my way through the process of preparing for the transplant. Correction: , at one point I refer to the AV graft as an artificial vascular graft. The correct term is arteriovenous Graft, which connects an artery with a vein allowing access for the dialysis to take place. Image Description: A stylised graphic of a woman with a ponytail walking with a white cane, next to an icon of an eye with curved lines suggesting vision or awareness. Below the graphic is the text:A Different Way of Seeing with Lois Strachan I'd love to hear from you – contact me at Web: https://www.loisstrachan.com/ LinkedIn: www.linkedin.com/in/lstrachan Facebook: https://www.facebook.com/loisstrachanspeaker This episode edited by Craig Strachan using Hindenburg PRO – find out more on Hindenburg.com Credits and music by Charlie Dyasi.

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: This episode was supported by Greater Manchester NHS who received support from Boehringer.  You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Bridge the gap between innovation and practice: are you unlocking the potential of novel agents in dialysis-dependent chronic kidney disease (CKD) anemia? Credit available for this activity expires: 10/31/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003063?ecd=bdc_podcast_libsyn_mscpedu

In this episode, Dr. David Traster sits down with Dr. Michael Lebowitz, DC and Dr. Noah Lebowitz, DC of Supreme Nutrition Products to uncover what's really driving the chronic disease epidemic — and how herbal medicine + integrative strategies can help turn the tide.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

This issue will review: 1.     Once-weekly Ultra-processed Foods and Diet Quality in Association With Long-term Weight Change and Progression to Type 2 Diabetes Among Individuals With a History of Gestational Diabetes Mellitus—A Prospective Study 2.     Plant-Based Dietary Patterns Associated With Reduced Risk of All-Cause Mortality in Diabetes Subgroups 3.     Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes- NEJM   4.     Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study 5.     GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.